Evaluation of the abuse potential of difelikefalin, a selective kappa‐opioid receptor agonist, in recreational polydrug users
Megan J. Shram(Altrecht GGZ), Frédérique Menzaghi(Cara Therapeutics (United States)), Lynn R. Webster(Adherent Technologies (United States)), Jack E. Henningfield(Univates), Catherine Munera(Cara Therapeutics (United States)), Jenny Qian(Cara Therapeutics (United States)), Michael E. Lewis(Genesis HealthCare), Robert H. Spencer(California Institute of Technology)
Cited by 32
Related Papers
Biochemical verification of tobacco use and cessation
|Nicotine & Tobacco Research|2002|1.8k
Predicting Aberrant Behaviors in Opioid-Treated Patients: Preliminary Validation of the Opioid Risk Tool
|Pain Medicine|2005|1.1k
Structure of the MscL Homolog from <i>Mycobacterium tuberculosis</i> : A Gated Mechanosensitive Ion Channel
|Science|1998|988
Blood Cannabinoids. I. Absorption of THC and Formation of 11-OH-THC and THCCOOH During and After Smoking Marijuana*
|Journal of Analytical Toxicology|1992|520
Risk Factors for Opioid-Use Disorder and Overdose
|Anesthesia & Analgesia|2017|504